ORION CORP.B UNSP.ADR 1/2 Net Assets

Latest as of March 2026: €1.12 Billion EUR ≈ $1.31 Billion USD

ORION CORP.B UNSP.ADR 1/2 net assets. Based on the latest financial reports, ORION CORP.B UNSP.ADR 1/2 (OFK0) has net assets worth €1.12 Billion EUR (≈ $1.31 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€2.08 Billion ≈ $2.43 Billion USD) and total liabilities (€956.70 Million ≈ $1.12 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore ORION CORP.B UNSP.ADR 1/2 (OFK0) equity growth momentum to track the company's year-over-year net asset growth rate.

Key Net Assets Metrics

Metric Value
Current Net Assets €1.12 Billion
% of Total Assets 53.98%
Annual Growth Rate 12.25%
5-Year Change N/A
10-Year Change N/A
Growth Volatility 12.16

Net Assets of ORION CORP.B UNSP.ADR 1/2 (2022–2025)

Net assets of ORION CORP.B UNSP.ADR 1/2 from 2022 to 2025. This chart illustrates how ORION CORP.B UNSP.ADR 1/2's net assets have evolved over time, based on quarterly financial data. See ORION CORP.B UNSP.ADR 1/2 (OFK0) balance sheet quality index to measure how much of total assets are equity-financed.

Annual Net Assets for ORION CORP.B UNSP.ADR 1/2 (2022–2025)

The table below shows the annual net assets of ORION CORP.B UNSP.ADR 1/2 from 2022 to 2025. For live market cap and overall valuation, see ORION CORP.B UNSP.ADR 1/2 (OFK0) total market value.

Year Net Assets Change
2025-12-31 €1.28 Billion
≈ $1.50 Billion		 +27.81%
2024-12-31 €1.00 Billion
≈ $1.17 Billion		 +12.91%
2023-12-31 €890.10 Million
≈ $1.04 Billion		 -1.98%
2022-12-31 €908.10 Million
≈ $1.06 Billion		 --

Equity Component Analysis

This analysis shows how different components contribute to ORION CORP.B UNSP.ADR 1/2's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 45.2% over the analyzed period, indicating profitable operations and earnings retention.

ORION CORP.B UNSP.ADR 1/2 Net Assets Breakdown (December 2025)

ORION CORP.B UNSP.ADR 1/2 net assets breakdown by equity component as of December 2025.

Component Amount Percentage
Retained Earnings €1.19 Billion 92.85%
Other Components €91.90 Million 7.15%
Total Equity €1.28 Billion 100.00%

ORION CORP.B UNSP.ADR 1/2 Competitors by Market Cap

The table below lists competitors of ORION CORP.B UNSP.ADR 1/2 ranked by their market capitalization.

Company Market Cap
SAINSBURY -J.- ADR/4 NEW
F:SUY
 $8.31 Billion
Brixmor Property
NYSE:BRX
 $8.31 Billion
Western Alliance Bancorporation
NYSE:WAL
 $8.32 Billion
Kinsale Capital Group Inc
NYSE:KNSL
 $8.33 Billion
Svenska Cellulosa Aktiebolaget SCA (publ)
ST:SCA-B
 $8.30 Billion
GETLINK ADR EO-40
F:TNU
 $8.29 Billion
RATIONAL Aktiengesellschaft
XETRA:RAA
 $8.29 Billion
WT Microelectronics Co Ltd
TW:3036
 $8.29 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in ORION CORP.B UNSP.ADR 1/2's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 1,005,000,000 to 1,284,500,000, a change of 279,500,000 (27.8%).
  • Net income of 500,300,000 contributed positively to equity growth.
  • Dividend payments of 231,100,000 reduced retained earnings.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income €500.30 Million +38.95%
Dividends Paid €231.10 Million -17.99%
Other Changes €10.30 Million +0.8%
Total Change €- 27.81%

Book Value vs Market Value Analysis

This analysis compares ORION CORP.B UNSP.ADR 1/2's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 3.97x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 5.59x to 3.97x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2022-12-31 €6.48 €36.20 x
2023-12-31 €6.34 €36.20 x
2024-12-31 €7.15 €36.20 x
2025-12-31 €9.13 €36.20 x

Capital Efficiency Dashboard

This dashboard shows how efficiently ORION CORP.B UNSP.ADR 1/2 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 38.95%
  • The company demonstrates strong efficiency in generating profits from shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 26.48%
  • • Asset Turnover: 0.94x
  • • Equity Multiplier: 1.56x
  • Recent ROE (38.95%) is above the historical average (33.65%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2022 38.49% 26.07% 0.89x 1.66x €258.69 Million
2023 24.36% 18.22% 0.83x 1.62x €127.79 Million
2024 32.83% 21.39% 0.95x 1.62x €229.40 Million
2025 38.95% 26.48% 0.94x 1.56x €371.85 Million

Industry Comparison

This section compares ORION CORP.B UNSP.ADR 1/2's net assets metrics with peer companies in the Drug Manufacturers - General industry.

Industry Context

  • Industry: Drug Manufacturers - General
  • Average net assets among peers: $181,182,941,315
  • Average return on equity (ROE) among peers: 10.43%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
ORION CORP.B UNSP.ADR 1/2 (OFK0) €1.12 Billion 38.49% 0.85x $8.31 Billion
Bayer AG NA (BAYN) $38.93 Billion 10.66% 2.21x $36.43 Billion
Cosmo Pharmaceuticals N.V (C43) $470.12 Million -6.90% 0.06x $993.61 Million
CSPC Pharmaceutical Group Limited (CVG) $9.13 Billion 20.61% 0.45x $10.04 Billion
CSPC PHARMACEUT.GR. ADR4 (CVGU) $33.87 Billion 12.78% 0.31x $11.04 Billion
GRIFOLS ADR 1/2/EO-50 (G0F) $8.61 Billion 1.82% 1.49x $4.21 Billion
Grifols S.A (G0FB) $7.51 Billion 0.56% 1.79x $4.42 Billion
GSK PLC SP. ADR/2 NEW (GS70) $12.79 Billion 38.52% 3.61x $101.34 Billion
Sanofi (SNW2) $59.03 Billion 7.29% 0.89x $105.72 Billion
ASTELLAS PHARMA UNSP.ADR (YPHA) $1.46 Trillion 8.50% 0.60x $19.55 Billion

About ORION CORP.B UNSP.ADR 1/2

F:OFK0 Germany Drug Manufacturers - General
Market Cap
$9.21 Billion
€7.88 Billion EUR
Market Cap Rank
#2467 Global
#510 in Germany
Share Price
€36.20
Change (1 day)
-1.09%
52-Week Range
€26.60 - €37.40
All Time High
€37.40
Categories
Companies in Germany Drug Manufacturers - General
About

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflam… Read more